Following the call from the UK’s chief medical officer to offer routine genome screening on the NHS, IPMI provider, Generali Global Health (GGH), has said genome testing is already routinely offered as part of their plans.
Marco Giacomelli, head of General Global Health, said “We added Genome Testing to our plan in early 2017, as we recognise this is critical in the effective treatment of cancer. This type of testing will become commonplace and enables a more precise healthcare pathway as the fight against cancer continues.”
GGH provides optional genome profiling for members diagnosed with cancer. This innovative swab-test identifies which course of treatment is most suitable based on analysis of the member’s genetic profile.
This means the member and their medical practitioner can have greater confidence in their chosen treatment plan.
Giacomelli added:“We agree with Dame Sally that this simple test can revolutionise the diagnosis and care of cancer sufferers in the future. We are one of the first insurers to offer this test to our members, but we believe it will become a widely used test globally.
“If the NHS can routinely provide this test it will position the UK as a leader in cancer diagnosis and treatment.”
Giacomelli’s comments come after Ross Campbell life / health chief underwriter, research & development at Gen Re, recently told Life Insurance International how genomics is becoming an essential issue for the life insurance industry as it would enable insurers to offer much more personalised policies.
With genetics and insurance, Campbell said fundamental issues are at stake. However, he argues it is clear there are potentially significant benefits for consumers who allow access to data on their lifestyle, activity patterns, medical history and genetic makeup.
Importantly, insurers would be able to offer much more personalised insurance policies that encourage engagement and improve outcomes for their customers, says Campbell.